Response to Dabrafenib and Trametinib in a Patient with an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer
07:30am - 03:35pm EDT - April 6, 2024


Response to Dabrafenib and Trametinib in a Patient with an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer icon

Abstract: JNCCN23-0570 https://jnccn.org/view/journal...


Author(s):
  • John Sharp, MD, Hematology and Medical Oncology Fellow, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Tags: Member Institution Case Reports

Display Label Action
NCCN - Uncommon BRAF NSCLC 2.29.24.pdf Download Handout